BR9914256A - Derivados de ácido 2,4-pentadienóico tendo atividade seletiva para receptores de retinóide x (rxr) - Google Patents

Derivados de ácido 2,4-pentadienóico tendo atividade seletiva para receptores de retinóide x (rxr)

Info

Publication number
BR9914256A
BR9914256A BR9914256-2A BR9914256A BR9914256A BR 9914256 A BR9914256 A BR 9914256A BR 9914256 A BR9914256 A BR 9914256A BR 9914256 A BR9914256 A BR 9914256A
Authority
BR
Brazil
Prior art keywords
formula
rxr
retinoid
receptors
acid derivatives
Prior art date
Application number
BR9914256-2A
Other languages
English (en)
Inventor
Vidyasagar Vuligonda
Kwok Yin Tsang
Jayasree Vasudevan
Roshantha A Chandraratna
Original Assignee
Allergan Sales Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Allergan Sales Inc filed Critical Allergan Sales Inc
Publication of BR9914256A publication Critical patent/BR9914256A/pt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D311/00Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/58Benzo[b]pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulphur atoms in position 2 or 4
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/04Antipruritics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/06Antipsoriatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/10Anti-acne agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/14Drugs for dermatological disorders for baldness or alopecia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/16Emollients or protectives, e.g. against radiation
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/02Nutrients, e.g. vitamins, minerals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/06Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C57/00Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
    • C07C57/46Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms containing six-membered aromatic rings and other rings, e.g. cyclohexylphenylacetic acid
    • C07C57/48Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms containing six-membered aromatic rings and other rings, e.g. cyclohexylphenylacetic acid having unsaturation outside the aromatic rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C57/00Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
    • C07C57/46Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms containing six-membered aromatic rings and other rings, e.g. cyclohexylphenylacetic acid
    • C07C57/50Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms containing six-membered aromatic rings and other rings, e.g. cyclohexylphenylacetic acid containing condensed ring systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/612Esters of carboxylic acids having a carboxyl group bound to an acyclic carbon atom and having a six-membered aromatic ring in the acid moiety
    • C07C69/618Esters of carboxylic acids having a carboxyl group bound to an acyclic carbon atom and having a six-membered aromatic ring in the acid moiety having unsaturation outside the six-membered aromatic ring
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00Systems containing only non-condensed rings
    • C07C2601/02Systems containing only non-condensed rings with a three-membered ring
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00Systems containing two condensed rings
    • C07C2602/02Systems containing two condensed rings the rings having only two atoms in common
    • C07C2602/04One of the condensed rings being a six-membered aromatic ring
    • C07C2602/10One of the condensed rings being a six-membered aromatic ring the other ring being six-membered, e.g. tetraline
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2603/00Systems containing at least three condensed rings
    • C07C2603/56Ring systems containing bridged rings
    • C07C2603/58Ring systems containing bridged rings containing three rings
    • C07C2603/70Ring systems containing bridged rings containing three rings containing only six-membered rings
    • C07C2603/74Adamantanes

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Dermatology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Cardiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Endocrinology (AREA)
  • Psychology (AREA)
  • Nutrition Science (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Toxicology (AREA)
  • Pulmonology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pyrane Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Patente de Invenção: <B>"DERIVADOS DE áCIDO 2,4-PENTADIENóICO TENDO ATIVIDADE SELETIVA PARA RECEPTORES DE RETINóIDE X (RXR)"<D>. Compostos da <B>Fórmula (1), Fórmula (2)<D> ou <B>Fórmula (3)<D> onde <B>X<D> é O, S ou (C<B>R~ 1~R~ 1~<D>)~ n~ onde n é 0, 1 ou 2; Y é um radical bivalente tendo a <B>Fórmula (4)<D> ou a <B>Fórmula (5)<D>, onde <B>o<D> é um número inteiro de 1 a 4 ou Y é uma radical arila bivalente ou heteroarila de 5 ou 6 elementos tendo 1 a 3 heteroátomos selecinados de N, S e O, os referidos grupos arila e heteroarila sendo não-substituídos ou substituídos por 1 a 3 grupos C~ 1-6~ alquila ou por 1 a 3 C~ 1-6~ fluoroalquila; e os símbolos restantes possuem o significado descrito na especificação, possuem atividade semelhantes aos agonistas seletivos de retinóide RXR.
BR9914256-2A 1998-10-01 1999-09-20 Derivados de ácido 2,4-pentadienóico tendo atividade seletiva para receptores de retinóide x (rxr) BR9914256A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/164,950 US6147224A (en) 1998-10-01 1998-10-01 2,4-pentadienoic acid derivatives having selective activity for retinoid X (RXR) receptors
PCT/US1999/021712 WO2000020370A1 (en) 1998-10-01 1999-09-20 2, 4-pentadienoic acid derivatives having selective activity for retinoid x (rxr) receptors

Publications (1)

Publication Number Publication Date
BR9914256A true BR9914256A (pt) 2001-07-03

Family

ID=22596791

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9914256-2A BR9914256A (pt) 1998-10-01 1999-09-20 Derivados de ácido 2,4-pentadienóico tendo atividade seletiva para receptores de retinóide x (rxr)

Country Status (17)

Country Link
US (1) US6147224A (pt)
EP (2) EP1117628B1 (pt)
JP (1) JP2002526516A (pt)
KR (2) KR20010075457A (pt)
CN (1) CN1328538A (pt)
AR (1) AR020691A1 (pt)
AT (1) ATE254593T1 (pt)
AU (1) AU757932B2 (pt)
BR (1) BR9914256A (pt)
CA (1) CA2346034A1 (pt)
DE (1) DE69912973T2 (pt)
ES (1) ES2207339T3 (pt)
HK (1) HK1039477A1 (pt)
NZ (1) NZ510528A (pt)
TW (1) TW580494B (pt)
WO (1) WO2000020370A1 (pt)
ZA (1) ZA200102635B (pt)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6566372B1 (en) 1999-08-27 2003-05-20 Ligand Pharmaceuticals Incorporated Bicyclic androgen and progesterone receptor modulator compounds and methods
JP2003508402A (ja) 1999-08-27 2003-03-04 リガンド・ファーマシューティカルズ・インコーポレイテッド アンドロゲン受容体モジュレーター化合物および方法
EP1212322A2 (en) 1999-08-27 2002-06-12 Ligand Pharmaceuticals Incorporated 8-substituted-6-trifluoromethyl-9-pyrido[3,2-g]quinoline compounds as androgen receptor modulators
CO5200852A1 (es) * 1999-09-14 2002-09-27 Lilly Co Eli Moduladores rxr con mejorado perfil farmacologico ceptores x de los retinoides
US6906046B2 (en) 2000-12-22 2005-06-14 Celltech R & D Inc. Pharmaceutical uses and synthesis of benzobicyclooctanes
US6495719B2 (en) 2001-03-27 2002-12-17 Circagen Pharmaceutical Histone deacetylase inhibitors
US7312247B2 (en) 2001-03-27 2007-12-25 Errant Gene Therapeutics, Llc Histone deacetylase inhibitors
US7842727B2 (en) 2001-03-27 2010-11-30 Errant Gene Therapeutics, Llc Histone deacetylase inhibitors
AU2002250401A1 (en) * 2001-03-27 2002-10-08 Circagen Pharmaceutical Histone deacetylase inhibitors
US8026280B2 (en) 2001-03-27 2011-09-27 Errant Gene Therapeutics, Llc Histone deacetylase inhibitors
US6388105B1 (en) * 2001-09-27 2002-05-14 Allergan Sales, Inc. Benzofuran, indole or benzothiophene 2,4-pentadienoic acid derivatives having selective activity for retinoid X (RXR) receptors
US6720423B2 (en) 2002-04-30 2004-04-13 Allergan, Inc. Dihydrobenzofuran and dihydrobenzothiophene 2,4-pentadienoic acid derivatives having selective activity for retinoid X (RXR) receptors
CA2486303C (en) 2002-05-22 2013-04-30 Errant Gene Therapeutics, Llc Histone deacetylase inhibitors based on alpha-ketoepoxide compounds
AU2003291097A1 (en) 2002-11-20 2004-06-15 Errant Gene Therapeutics, Llc Treatment of lung cells with histone deacetylase inhibitors
US6683092B1 (en) 2003-04-09 2004-01-27 Allergan, Inc. [3-(c5-14alkyl-2-oxo-1,2,3,4-tetrahydro-quinolin-6-yl)-3-oxo-propenyl]-phenyl and [3-(c5-14alkyl-2-oxo-1,2,3,4- tetrahydro-quinolin-6-yl)-3-oxo-propenyl]-heteroaryl derivatives having anti-tumor activity
US6734193B1 (en) 2003-06-03 2004-05-11 Allergan, Inc. (1,2,3,4-tetrahydroquinolin-8-yl)-heptatrienoic acid derivatives having serum glucose reducing activity
US6936636B2 (en) * 2003-06-26 2005-08-30 Allergan, Inc. 5-[phenyl-tetrahydronaphthalene-2-yl dihydronaphthalen-2-yl and heteroaryl-cyclopropyl]-pentadienoic acid derivatives having serum glucose reducing activity
US6887896B1 (en) 2003-10-29 2005-05-03 Allergan, Inc. 7-[(7-Alkoxy)-chrom-3-en-6-yl]-heptatrienoic acid and 7-[(3-alkoxy)-5,6-dihydronaphthalen-2-yl]-heptatrienoic acid derivatives having serum glucose reducing activity
ES2690304T3 (es) 2005-09-30 2018-11-20 Io Therapeutics, Llc Tratamiento del cáncer con agonistas específicos de RXR
US20070185055A1 (en) * 2006-02-06 2007-08-09 Guang Liang Jiang Method for treating cachexia with retinoid ligands
CN104114171A (zh) 2011-12-13 2014-10-22 Io治疗公司 使用rxr激动剂的自身免疫紊乱的治疗
CN105308026B (zh) * 2013-07-09 2018-12-21 东曹株式会社 具有金刚烷基的环状吖嗪化合物、制造方法、以及以该化合物作为构成成分的有机电致发光元件
CN108289958A (zh) 2015-10-31 2018-07-17 Io治疗公司 使用rxr激动剂和甲状腺激素的组合治疗神经系统紊乱
CN115227825A (zh) 2016-03-10 2022-10-25 Io治疗公司 Rxr激动剂和甲状腺激素在制备用于治疗自身免疫疾病的药物中的用途
WO2017155578A1 (en) 2016-03-10 2017-09-14 Io Therapeutics, Inc. Treatment of muscular disorders with combinations of rxr agonists and thyroid hormones
US11517549B2 (en) 2017-09-20 2022-12-06 Io Therapeutics, Inc. Treatment of disease with esters of selective RXR agonists
SG11202003733RA (en) * 2017-11-17 2020-05-28 Io Therapeutics Inc Compounds and synthetic methods for the preparation of retinoid x receptor-specific retinoids
US10966950B2 (en) 2019-06-11 2021-04-06 Io Therapeutics, Inc. Use of an RXR agonist in treating HER2+ cancers
WO2023108012A1 (en) 2021-12-07 2023-06-15 Io Therapeutics, Inc. Use of an rxr agonist and taxanes in treating her2+ cancers

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8826760D0 (en) * 1988-11-16 1988-12-21 Wellcome Found Pesticides
DK0617614T3 (da) * 1991-12-18 1998-09-28 Salk Inst For Biological Studi Midler til modulering af processer medieret af retinoide receptorer og forbindelser anvendlige dertil
CA2133587C (en) * 1992-04-22 2008-11-18 Marcus F. Boehm Compounds having selectivity for retinoid x receptors
JPH08511027A (ja) * 1993-01-11 1996-11-19 リガンド・ファーマシューティカルズ・インコーポレーテッド レチノイドxレセプターに対して選択的な活性を有する化合物、およびレチノイドxレセプターによって媒体されたプロセスの調節手段
US5455265A (en) * 1993-02-11 1995-10-03 Allergan, Inc. Method of treatment with compounds having selective agonist-like activity on RXR retinoid receptors
JP2848964B2 (ja) * 1994-08-10 1999-01-20 エフ・ホフマン−ラ ロシュ アーゲー レチノイン酸x受容体リガンド
IL116259A (en) * 1994-12-19 2000-07-16 American Cyanamid Co Analogs of 9-cis retinoic acid and their use
US5648514A (en) * 1994-12-29 1997-07-15 Allergan Substituted acetylenes having retinoid-like biological activity
US5543534A (en) * 1994-12-29 1996-08-06 Allergan Acetylenes disubstituted with a 5 substituted tetrahydronaphthyl group and with an aryl or heteroaryl groups having retinoid-like biological activity
US5675033A (en) * 1995-06-06 1997-10-07 Allergan 2,4-pentadienoic acid derivatives having retinoid-like biological activity
US5776699A (en) * 1995-09-01 1998-07-07 Allergan, Inc. Method of identifying negative hormone and/or antagonist activities
JP2002515025A (ja) * 1995-10-06 2002-05-21 リガンド・ファーマシューティカルズ・インコーポレイテッド ダイマー選択的rxrモジュレーターおよびその使用方法
US5723666A (en) * 1996-06-21 1998-03-03 Allergan Oxime substituted tetrahydronaphthalene derivatives having retinoid and/or retinoid antagonist-like biological activity
US5728846A (en) * 1996-12-12 1998-03-17 Allergan Benzo 1,2-g!-chrom-3-ene and benzo 1,2-g!-thiochrom-3-ene derivatives
CA2366186C (en) * 1999-03-08 2007-05-15 Basilea Pharmaceutica Ag Retinoid antagonists and use thereof

Also Published As

Publication number Publication date
EP1388534A3 (en) 2004-02-25
DE69912973D1 (de) 2003-12-24
ZA200102635B (en) 2002-10-18
KR20010075457A (ko) 2001-08-09
EP1388534A2 (en) 2004-02-11
AR020691A1 (es) 2002-05-22
KR20060118367A (ko) 2006-11-23
WO2000020370A1 (en) 2000-04-13
US6147224A (en) 2000-11-14
EP1117628A1 (en) 2001-07-25
AU757932B2 (en) 2003-03-13
NZ510528A (en) 2003-04-29
JP2002526516A (ja) 2002-08-20
ES2207339T3 (es) 2004-05-16
TW580494B (en) 2004-03-21
AU6051399A (en) 2000-04-26
DE69912973T2 (de) 2004-07-22
CA2346034A1 (en) 2000-04-13
EP1117628B1 (en) 2003-11-19
HK1039477A1 (en) 2002-04-26
CN1328538A (zh) 2001-12-26
ATE254593T1 (de) 2003-12-15

Similar Documents

Publication Publication Date Title
BR9914256A (pt) Derivados de ácido 2,4-pentadienóico tendo atividade seletiva para receptores de retinóide x (rxr)
KR870000289A (ko) 트리시클로데칸의 (메트)-아크릴산 유도체의 제조방법
BR9909423A (pt) Composição e método para produzir politioéteres tendo cadeias de metila pendentes
BR9913592A (pt) Compostos, processo de preparação dos compostos, e, composições farmacêuticas
ATE270103T1 (de) Aminophenoxyessigsäure derivate als neuroschützende mittel
EA200200708A1 (ru) Производные бензазола и их применение в качестве модуляторов jnk
BR0307607A (pt) Derivados de carbonilamino como inibidores de histona desacetilase
BR0001509A (pt) Derivados de oxima e o seu uso como ácidos latentes
DK1117648T3 (da) Tetrahydroquinolinderivater med selektiv virkning for retinoid X receptorer
DK0608847T3 (da) Carbocykliske sulfonamider som agonister eller antagonister for PGEZ
CY1106381T1 (el) Βιοκτονος συνθεση καθαρισμου
KR880003622A (ko) 카테콜유도체 및 그것을 함유하는 중추신경계 퇴행성 질환의 진행방지 및 치료제
BR9811691A (pt) ácidos éter-carboxìlicos como dispersantes de asfaltenos em óleos brutos.
EA200200098A1 (ru) Ароматические сложные эфиры для маркировки или мечения нефтепродуктов
RU94023250A (ru) 2,3-дигидро-1,4-бензодиоксин-5-ил-пиперазиновые производные, обладающие 5-нт1а-антагонистической активностью, способы их получения, фармкомпозиция на их основе, получение ее и способ лечения расстройств нервной системы
DE3665711D1 (de) Novel guanidinomethylbenzoic acid derivatives
KR920703512A (ko) 단백질 활성효소 c(protein kinase c)를 방해하는 1, 4-비스-(아미노-하이드록시알킬아미노)-안트라퀴논
AR016175A1 (es) Compuestos derivados del acido dihidroxihexanoico, su uso para la preparacion de medicamentos y composiciones de los mismos.
EA200970497A1 (ru) Производные пиррола, их получение и их применение в терапии
KR890000457A (ko) 티오펜 유도체
MX7122E (es) Procedimiento para la preparacion de derivados de tiometilpiridina
BRPI9710537B8 (pt) derivados da eritromicina, composições farmacêuticas, bem como processo para preparação dos mesmos.
NO308249B1 (no) Nye indan-2-mercaptoacetylamid-disulfidderivater som er anvendbare som inhibitorer av enkefalinase
KR930702269A (ko) 포스포리파제 a2저해 물질
RU94031212A (ru) Производные тетразолуксусной кислоты, фармацевтическая композиция на их основе

Legal Events

Date Code Title Description
B25A Requested transfer of rights approved

Free format text: ALLERGAN SALES, LLC (US)

B25A Requested transfer of rights approved

Free format text: ALLERGAN, INC (US)

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: INDEFIRO O PRESENTE PEDIDO DE PATENTE DE ACORDO COM ART. 8O DA LPI